We asked, you answered: Labiotech’s 2026 reader survey results

Labiotech exists to be genuinely useful to those building the future of biotech. Recently, they conducted a survey among their newsletter subscribers, their most active and engaged readers, to understand their preferences, concerns, and expectations. The survey included scientists, investors, business developers, executives, and CEOs from various countries and industries.

The respondents were predominantly senior decision-makers, with more than 80% being managers, owners, directors, presidents, VPs, or CEOs. These professionals are involved in purchasing decisions at their workplaces and work across various sectors within the biotech industry, including research, business development, product management, consulting, and operations.

Geographically, Labiotech's primary audience is Europe and North America, with France, the UK, Germany, India, Asia-Pacific, and other countries represented. The engagement numbers indicate that more than 80% of the readers engage with Labiotech's content at least once a week, making it a part of their routine.

The newsletter is the most popular way to consume Labiotech content, with 42% of respondents favoring it. Articles on the website closely follow. However, several formats, such as webinars, podcasts, partner resources, and LinkedIn posts, have low awareness but show potential for growth.

Trust is a significant factor in the relationship between Labiotech and its readers. Nearly three-quarters of the respondents rate their familiarity with Labiotech at seven out of ten or above, and nearly 40% have been reading the newsletter for over two years. The majority of respondents rate Labiotech's content quality at seven out of ten or higher, and about 80% would recommend Labiotech to a colleague.

The quality and reliability of the content, its depth and analytical rigor, the range of topics covered, the European focus, and a fresh perspective are some of the key factors contributing to the positive perception of Labiotech. Readers are primarily interested in discovering promising biotech companies, scientific advances, and emerging innovations, not just big names. They also want to stay up to date on major industry news, trends, funding rounds, and strategic moves made by large pharmaceutical companies.

In terms of therapeutic areas, oncology leads, followed by immunology and autoimmune conditions, genetic and genomic diseases, and neurology and CNS. Approaches such as cell therapy, protein/biologics, gene therapy, gene editing, and AI-driven drug discovery also rank high. Despite these dominant areas, interest remains strong across a wide range of therapeutic areas and approaches, including cardiovascular, infectious diseases, microbiome, peptide therapeutics, and more.

Europe and North America remain the primary areas of interest for Labiotech's coverage, but there is a strong emphasis on Labiotech's European perspective, as it differentiates them from the predominantly American media landscape. Additionally, Asia-Pacific and emerging regions like Latin America and Africa are gaining attention from readers.

Finally, respondents consistently asked for new formats, including infographics, visual summaries, short video explainers, virtual and in-person events, and practical guides and playbooks. The goal is to make Labiotech content more accessible and digestible for readers, whether they are on the go, in meetings, or between experiments.